Proton pump inhibitor treatment aggravates bacterial translocation in patients with advanced cirrhosis and portal hypertension
Abstract: Recent studies have linked proton pump inhibitor (PPI) treatment to increased complications of cirrhosis, such as bacterial infections and hepatic encephalopathy. However, the underlying pathophysiological mechanisms remain unclear. The present study investigated the hypothesis that PPI treatment may promote adverse effects in patients with advanced cirrhosis by affecting subclinical bacterial translocation (BT) from the gut into the portal venous bloodstream. Blood samples from the portal vein were obtained during implantation of a transjugular intrahepatic portosystemic shunt (TIPS) in a total of 80 cirrhosis patients with PPI treatment (PPI group, n = 57) and without PPI treatment (no-PPI group, n = 23). BT was identified using a 16S ribosomal RNA gene (V1V2 region) polymerase chain reaction. The microbiota composition in the portal venous blood samples was further analyzed by deep amplicon sequencing. Indeed, the prevalence of BT was significantly higher in the PPI group compared to the no-PPI group (86.0% vs 52.2%, P = 0.001). Importantly, this effect was not attributable to group differences in the severity of cirrhosis, parameters of portal hypertension, or medication. Microbiome analyses showed significantly increased alpha-diversity (Shannon) in the portal venous blood of the PPI group. Taxonomic analyses revealed significantly increased Streptococcus abundances in these patients. The present study reveals aggravated BT in patients with advanced cirrhosis and portal hypertension receiving PPI therapy. Increased BT could be an important pathomechanism contributing to the adverse effects of PPI treatment in patients with cirrhosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
mBio. - 14, 5 (2023) , mbio.00492-23, ISSN: 2150-7511
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2023
- DOI
-
10.1128/mbio.00492-23
- URN
-
urn:nbn:de:bsz:25-freidok-2388518
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
Entstanden
- 2023
Ähnliche Objekte (12)
Proton pump inhibitor treatment is associated with acute-on-chronic liver failure in patients with advanced cirrhosis
Follicular T helper cell signatures in primary biliary cholangitis and primary sclerosing cholangitis
The transjugular intrahepatic portosystemic shunt: Smaller stent diameters are required to optimize pressure response
No evidence for genotype-phenotype correlation in NPHS1 and NPHS2 mutations
Rolle von CD4+CD25+ regulatorischen T-Zellen bei der chronischen HCV-Infektion
Pattern formation and synchronization in excitable systems under the influence of spatiotemporal colored noise
Fibrosis progression in patients with Budd–Chiari syndrome and transjugular intrahepatic portosystemic shunt (TIPS): a long-term study using transient elastography
A prospective, multicentre study in acute non‐cirrhotic, non‐malignant portal vein thrombosis: comparison of medical and interventional treatment
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: a comparative analysis in a European real-world cohort
Die Haftung des "shadow director" einer englischen Kapitalgesellschaft : der Haftungsdurchgriff auf den beherrschenden Gesellschafter und die Konzernobergesellschaft im englischen Recht
Plasma cyclic guanosine monophosphate is a promising biomarker of clinically significant portal hypertension in patients with liver cirrhosis
Timing of the treatment of portal vein thrombosis in patients with cirrhosis : : a German hepatologist’s perspective
Proton pump inhibitor treatment is associated with acute-on-chronic liver failure in patients with advanced cirrhosis
Follicular T helper cell signatures in primary biliary cholangitis and primary sclerosing cholangitis
The transjugular intrahepatic portosystemic shunt: Smaller stent diameters are required to optimize pressure response
No evidence for genotype-phenotype correlation in NPHS1 and NPHS2 mutations
Rolle von CD4+CD25+ regulatorischen T-Zellen bei der chronischen HCV-Infektion
Pattern formation and synchronization in excitable systems under the influence of spatiotemporal colored noise
Fibrosis progression in patients with Budd–Chiari syndrome and transjugular intrahepatic portosystemic shunt (TIPS): a long-term study using transient elastography
A prospective, multicentre study in acute non‐cirrhotic, non‐malignant portal vein thrombosis: comparison of medical and interventional treatment
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: a comparative analysis in a European real-world cohort
Die Haftung des "shadow director" einer englischen Kapitalgesellschaft : der Haftungsdurchgriff auf den beherrschenden Gesellschafter und die Konzernobergesellschaft im englischen Recht
Plasma cyclic guanosine monophosphate is a promising biomarker of clinically significant portal hypertension in patients with liver cirrhosis
Timing of the treatment of portal vein thrombosis in patients with cirrhosis : : a German hepatologist’s perspective
Proton pump inhibitor treatment is associated with acute-on-chronic liver failure in patients with advanced cirrhosis
Follicular T helper cell signatures in primary biliary cholangitis and primary sclerosing cholangitis
The transjugular intrahepatic portosystemic shunt: Smaller stent diameters are required to optimize pressure response
No evidence for genotype-phenotype correlation in NPHS1 and NPHS2 mutations
Rolle von CD4+CD25+ regulatorischen T-Zellen bei der chronischen HCV-Infektion
Pattern formation and synchronization in excitable systems under the influence of spatiotemporal colored noise
Fibrosis progression in patients with Budd–Chiari syndrome and transjugular intrahepatic portosystemic shunt (TIPS): a long-term study using transient elastography
A prospective, multicentre study in acute non‐cirrhotic, non‐malignant portal vein thrombosis: comparison of medical and interventional treatment
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: a comparative analysis in a European real-world cohort
Die Haftung des "shadow director" einer englischen Kapitalgesellschaft : der Haftungsdurchgriff auf den beherrschenden Gesellschafter und die Konzernobergesellschaft im englischen Recht
Plasma cyclic guanosine monophosphate is a promising biomarker of clinically significant portal hypertension in patients with liver cirrhosis